PF-05230907

PF-05230907 is a recombinant activated Factor X variant developed as a biologic drug for the treatment of acute intracerebral hemorrhage. It acts as an activator of coagulation factor X (FXa), aiming to promote hemostasis and limit bleeding in patients with brain hemorrhage. The drug is administered intravenously and has been evaluated in phase 1 clinical trials, where it demonstrated tolerability across a range of doses, with thrombotic events observed only at the highest dose level tested. Its mechanism involves enhancing coagulation through activation of FXa, which plays a central role in the blood clotting cascade. PF-05230907 was developed by Pfizer and has received orphan drug designation for intracerebral hemorrhage[1][2][4][5][7].